ESMO 2022 | Prognostic value of beta-2 adrenergic receptor levels in HER2+ breast cancer

Evandro De Azambuja, MD, PhD, Jules Bordet Institute, Brussels, Belgium, discusses a post-hoc analysis of the NCCTG-N9831 trial (NCT00005970) which investigated chemotherapy plus trastuzumab versus chemotherapy alone in the adjuvant setting for patients with HER2+ early-stage breast cancer. The primary endpoint of the trial was disease-free survival. The analysis looked at the prognostic value of beta-2 adrenergic receptor gene expression and the results suggested that patients with high expression of this receptor have better disease-free survival and response to trastuzumab. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.